WASHINGTON — Steve Ubl is stepping down as CEO of the Pharmaceutical Research and Manufacturers of America after more than a decade leading the brand drug industry’s main trade group.
Ubl plans to depart by the end of the year and will remain in his position until a new leader is found, according to a PhRMA statement.
Ubl led the organization during tumultuous times that included the Covid-19 pandemic and aggressive political attacks on drug prices. Democrats passed a law directing Medicare to negotiate drug prices, and the Trump administration struck voluntary deals with individual drugmakers aimed at lowering U.S. prices to levels in other high-income countries.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
